JAK Inhibition in STAT1 Gain-of-Function--Mediated Treatment-Resistant Autoimmune Hepatitis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      AUTOIMMUNE hepatitis; STAT proteins; CHRONIC active hepatitis; BIOLOGICALS; JUVENILE diseases
    • Abstract:
      The article presents a case study of a 21-month-old girl with treatment-resistant autoimmune hepatitis and a STAT1 gain-of-function mutation. It is reported that despite initial therapy, the patient experienced severe relapses. It is further reported that treatment with the JAK inhibitor baricitinib led to significant improvement, emphasizing the potential efficacy of targeted immune treatments in specific genetic variants associated with autoimmune hepatitis.